Company Presentation

March 2021

Allena Pharmaceuticals, Inc.

These slides, and the accompanying presentation, contain forward-looking statements and information. The use of words such as "may," "might," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "project," "intend," "future," "potential," or "continue," and other similar expressions are intended to identify forward-looking statements. All forward-looking statements are based on estimates and assumptions by our management that, although we believe them to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that we expected, including those risks and uncertainties that are described under the heading "Risk Factors" in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, as well as discussions of potential risks, uncertainties and other important factors in our subsequent filings with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

This presentation also contains estimates and other statistical data made by independent parties and us relating to market size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk.

2020 Accomplishments Position Allena for Long-term Growth

SIGNIFICANT MILESTONES ACHIEVED IN 2020…

WITH KEY UPCOMING VALUE DRIVERS IN 2021 & 2022

✓ Streamlined URIROX-2 design, reducing target length and cost of trial

  • ✓ Expanded URIROX-2 into new sites and geographies

    2Q21

    Initiate ALLN-346 Phase 1b multiple-ascending dose trial in healthy volunteers

    3Q21

    Initiate Phase 2a program in patients with hyperuricemia and CKD

  • ✓ Presented data demonstrating consistent reloxaliase treatment effect across Phase 2 and 3 studies

  • ✓ Completed Phase 1 clinical study of ALLN-346 in healthy volunteers: ALLN-346 well-tolerated and non-absorbed

    3Q21 4Q21 2021

    ALLN-346 Phase 1b MAD safety data Initial ALLN-346 Phase 2a data

    Leverage platform to expand preclinical pipeline into at least one additional metabolic disorder

  • ✓ Raised $70M+ through multiple financings, providing cash runway through the fourth quarter of 2021

2Q - 3Q22

4Q22 - 1Q23

URIROX-2 interim analysisURIROX-2 topline data for BLA submission

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original document
  • Permalink

Disclaimer

Allena Pharmaceuticals Inc. published this content on 09 March 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 March 2021 12:06:03 UTC.